维持性血液透析患者血镁水平与心脏瓣膜钙化的关系

doi:10.3969/j.issn.1006-6233.2018.02.005

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1322 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the relation between serum magnesium and cardiar valve calcification(CVC) in maintenance hemodialysis(MHD) patients. Methods: Patients with age≥18 years old,maintenance hemodialysis for ≥ 3 months were enrolled in this study.We collected their clinical data and blood biochemical indexes,CVC was measured by echocardiography. Logistic regression was used to analyze the relation between serum magnesium and CVC. Results: ①Among 149 MHD patients, serum magnesium average was 1.08±0.16mmol/L and 100 cases were high serum magnesium (67.1%),49 cases were normal serum magnesium(32.9%).98 cases were with CVC (65.8%). There were 60 cases with CVC (60.0%) in the high blood magnesium group, which were significantly lower than those 38 with CVC in the normal serum magnesium. ②Age, dialysis age, coronary heart disease, correction of calcium and serum scale were significantly higher in CVC group than non-CVC group (P <0.05). Serum magnesium level and the incidence of high serum magnesium were significantly higher in non-CVC group than CVC group (P <0.05). ③Logistic regression analysis dispaly: Serum magnesium was independent negatively associated with CVC (P = 0.001); age , dialysis age, serum phosphorus were independent positively associated with CVC (P＜0.05). Serum magnesium was independently negatively associated with MVC,AVC,MVC and AVC (P＜0.05). Serum phosphorus was independently positively associated with MVC, AVC, MVC and AVC (P＜0.05). Dialysis age was independently positively associated with MVC (P＜0.05). Age was independently positively associated with AVC (P＜0.001). Conclusion: The higher prevalence of serum magnesium, the higher serum magnesium and CVC in MHD patients, high serum magnesium can reduce the incidence of CVC in MHD patients; high serum phosphorus is an independent risk factor for CVC.

Key words： Serum magnesium Hemodialysis Cardiar valve Calcification

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.02.005 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I2/197

[1] Chen X N,Chen Z J,Ma X B,et al.Aortic artery and cardiac valve calcification are associated with mortality in Chinese hemodialysis patients:A 3.5 years follow-up[J].Chin Med (Engl),2015,128(20):2764~2771.
[2] Owens D S, Budoff M J, Katz R, et al. Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population [J]. JACC Cardiovasc Imaging, 2012,5(6): 619~625.
[3] 金咏菊,雷娟,王颖,等.血液透析患者血镁水平及相关营养状况分析[J].中国血液净化,2015,14(11):658~661.
[4] Li L,Streja E,Rhee C M,et al.Hypomagnesemia and Mortality in Incident Hemodialysis Patients[J].Am Kidney Dis,2015,66(6):1047~1055.
[5] 白亚玲,徐金升,靳晶晶.高镁对高磷诱导血管钙化的影响及其机制[J].中华肾脏病杂志,2015,1(31):37~42.
[6] Wong M,Tei C,Shah P M.Sensitivity and specificity of two-dimensional echocardiography in the detection of valvular calcification[J].Chest,1983,84(4):423~427.
[7] 王莉,李贵森,刘志红.中华医学会肾脏病学分会《慢性肾脏病矿物质和骨异常诊治指导》.肾脏病与透析肾移植杂志,2013,22(6):554~559.
[8] Ivanovski O, Nikolow IG, Joki N, et al.The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice[J]. Atherosclerosis,2009,205(1):55~62.
[9] 张磊,王志奎,马金玲,等.维持性血液透析及腹膜透析患者心脏瓣膜钙化的评估[J].实用医学杂志,2016,32(7): 1130~1132.
[10] 张晓玲,白久旭,郝峻烽,等.维持性血液透析患者心脏瓣膜钙化与左心室肥厚相关因素分析[J].中国血液净化,2016,15(1):18~21.
[11] Tzanakis I, Pras A, Kounali D, et al.Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium[J]. Nephrol Dial Transplant,1997,12(9):2036~2037.
[12] Rodriguez-ortiz M E,Canalejo A,HerenciaA C,et al.Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration[J].Nephrol Dial Transplant,2014,29(2):282~289.
[13] Tzanakis I P,Stamataki E E,Papadaki A N,et al.Magnesium retards the progress of the arterial calcifications in hemodialysis patients:a pilot study[J].Int Urol Nephrol,2014,46(11):2199~2205.
[14] Patricia J M,Aan A,Ivo L, et al. Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients[J]. Blood Purif ,2014,38(3~4):244~252.
[15] Boskey AL, Posner AS.Effect of magnesium on lipid-induced calcification: an in vitro model for bone mineralization[J]. Calcif Tissue Int,1980,32(2):139~143.
[16] Iguchi A,Watanabe Y,Iino N,et al.Serum magnesium concentration is inversely associated with fibroblast growth factor 23 in haemodialysis patients[J].Nephrology (Carlton),2014,19(3):667~671.
[17] Ott S M.Therapy for patients with CKD and low bone mineral density[J].Nat Rev Nephrol,2013,9(11): 681~692.
[18] Montezano AC, Zimmerman D, Yusuf H, et al.Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium[J]. Hypertension,2010,56(3):453~462.
[19] Navarro JF,Mora C,Garcia J.Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis[J]. Semin Dial,2009,22(1):37~44.
[20] Douban S, Brodsky MA, Whang DD, et al.Significance of magnesium in congestive heart failure[J]. Am Heart,1996,132(3):664~671.
[21] 贾凤玉,徐斌,龚德华,等.维持性血液透析患者心血管钙化的发生率及分布特点[J].肾脏病与透析肾移植杂志,2014,23(5):401~406.